This study describes an integrated treatment approach that was implemented to enhance functional recovery in first-episode psychotic patients. Patients were randomized to two treatment conditions: either to an integrated treatment approach: pharmacotherapy, psychosocial treatment, and psychoeducation (experimental group: ) or to medication alone (control group: ). Patients were evaluated at baseline and after one year of treatment. Functional recovery was assessed according to symptomatic and functional remission. At the end of treatment, experimental patients showed a 94.9% of symptomatic remission compared to 58.8% of the control group. Functional remission was 56.4% for the experimental group and 3.6% for the control group, while 56.4% of the experimental group met both symptomatic and functional remission criteria and were considered recovered compared to 2.9% of the control group. 1. Introduction Schizophrenia-spectrum disorders are characterized by the presence of psychotic symptoms, cognitive deficits, poor quality of life, and psychosocial deterioration [1–4]. Of all illnesses that afflict humans, schizophrenia is considered the 7th most disabling [5]. While perhaps only 1% of the population has schizophrenia, 30% experience an onset of psychotic symptoms by age 18 [6, 7]. Most patients are likely to experience multiple episodes of acute symptomatology, causing severe long-term functional impairment [8]. Relapse can be expected in 70% of patients after the first episode [9]. Intervention strategies for first-episode psychosis include implementation of pharmacological treatment and managing side effects. Psychoeducation is relevant for optimizing the management of side effects and promoting compliance with medication. Once the acute episode has been resolved, emphasis should focus on relapse prevention. The next stage would include implementation of psychosocial intervention facilitating compliance with medication, learning the warning signs of relapse, managing stressors, solving family problems, plus preparing to reestablish social relations and work or school activities that were interrupted [10, 11]. Pharmacological and psychosocial treatment strategies offer hope of preventing progression to long-term psychosis and moving toward a new recovery model for early psychosis. It is aimed at improving psychosocial functioning and promoting independent living in the community. Two key elements have been considered in the recovery model: symptomatic remission and functional recovery. Antipsychotic medication normally is prescribed for first-episode
References
[1]
T. Burns and D. Patrick, “Social functioning as an outcome measure in schizophrenia studies,” Acta Psychiatrica Scandinavica, vol. 116, no. 6, pp. 403–418, 2007.
[2]
I. Melle, U. Haahr, S. Friis et al., “Reducing the duration of untreated first-episode psychosis—effects on baseline social functioning and quality of life,” Acta Psychiatrica Scandinavica, vol. 112, no. 6, pp. 469–473, 2005.
[3]
P. Rocca, F. Castagna, T. Mongini, C. Montemagni, and F. Bogetto, “Relative contributions of psychotic symptoms and insight to quality of life in stable schizophrenia,” Psychiatry Research, vol. 177, no. 1-2, pp. 71–76, 2010.
[4]
D. I. Velligan, R. S. Kern, and J. M. Gold, “Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies,” Schizophrenia Bulletin, vol. 32, no. 3, pp. 474–485, 2006.
[5]
World Health Organization, “World Health Report. Mental health: new understanding, new hope,” WHO, Geneva, Switzerland, 2001.
[6]
P. M. Galdos, J. J. Van Os, and R. M. Murray, “Puberty and the onset of psychosis,” Schizophrenia Research, vol. 10, no. 1, pp. 7–14, 1993.
[7]
J. McGrath, S. Saha, D. Chant, and J. Welham, “Schizophrenia: a concise overview of incidence, prevalence, and mortality,” Epidemiologic Reviews, vol. 30, no. 1, pp. 67–76, 2008.
[8]
S. Kasper, “First-episode schizophrenia: the importance of early intervention and subjective tolerability,” Journal of Clinical Psychiatry, vol. 60, no. 23, supplement, pp. 5–9, 1999.
[9]
N. Müller, “Mechanisms of relapse prevention in schizophrenia,” Pharmacopsychiatry, vol. 37, no. 2, pp. S141–S147, 2004.
[10]
M. Birchwood and E. Spencer, “Early intervention in psychotic relapse,” Clinical Psychology Review, vol. 21, no. 8, pp. 1211–1226, 2001.
[11]
A. K. Mattai, J. L. Hill, and R. K. Lenroot, “Treatment of early-onset schizophrenia,” Current Opinion in Psychiatry, vol. 23, no. 4, pp. 304–310, 2010.
[12]
D. L. Penn, E. J. Waldheter, D. O. Perkins, K. T. Mueser, and J. A. Lieberman, “Psychosocial treatment for first-episode psychosis: a research update,” American Journal of Psychiatry, vol. 162, no. 12, pp. 2220–2232, 2005.
[13]
J. A. Lieberman, G. Tollefson, M. Tohen et al., “Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol,” American Journal of Psychiatry, vol. 160, no. 8, pp. 1396–1404, 2003.
[14]
M. Lambert, T. De Marinis, J. Pfeil, D. Naber, and A. Schreiner, “Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment,” European Psychiatry, vol. 25, no. 4, pp. 220–229, 2010.
[15]
M. Tohen, S. M. Strakowski, C. Zarate et al., “The McLean-Harvard First-Episode Project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis,” Biological Psychiatry, vol. 48, no. 6, pp. 467–476, 2000.
[16]
J. A. Lieberman, “Prediction of outcome in first-episode schizophrenia,” Journal of Clinical Psychiatry, vol. 54, no. 3, pp. 13–17, 1993.
[17]
L. P. Henry, G. P. Amminger, M. G. Harris et al., “The EPPIC follow-up study of first episode psychosis: longer term clinical and functional outcome 7 years after index admission,” Journal of Clinical Psychiatry, vol. 71, no. 6, pp. 716–728, 2010.
[18]
J. Addington, J. Young, and D. Addington, “Social outcome in early psychosis,” Psychological Medicine, vol. 33, no. 6, pp. 1119–1124, 2003.
[19]
A. K. Malla and R. M. G. Norman, “Early intervention in schizophrenia and related disorders: advantages and pitfalls,” Current Opinion in Psychiatry, vol. 15, no. 1, pp. 17–23, 2002.
[20]
P. E. Bebbington, T. Craig, P. Garety et al., “Remission and relapse in psychosis: operational definitions based on case-note data,” Psychological Medicine, vol. 36, no. 11, pp. 1551–1562, 2006.
[21]
T. J. Hudson, R. R. Owen, C. R. Thrush, T. L. Armitage, and P. Thapa, “Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia,” Journal of Clinical Psychiatry, vol. 69, no. 1, pp. 74–80, 2008.
[22]
P. D. McGorry, J. Edwards, C. Mihalopoulos, S. M. Harrigan, and H. J. Jackson, “EPPIC: an evolving system of early detection and optimal management,” Schizophrenia Bulletin, vol. 22, no. 2, pp. 305–326, 1996.
[23]
Y. Tang, G. Wong, C. Lui, et al., “Early interventions for psychosis in Hong Kong the EASY program,” Early Intervention Psychiatry, vol. 3, pp. 214–219, 2010.
[24]
A. P. Morrison, P. French, S. Parker et al., “Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk,” Schizophrenia Bulletin, vol. 33, no. 3, pp. 682–687, 2007.
[25]
P. Power, P. Mcguire, E. Iacoponi, et al., “Early onset (LEO) and outreach & support in south London (OASIS) service,” Early Intervention Psychiatry, vol. 1, pp. 97–113, 2007.
[26]
J. Klosterkotter, S. Ruhman, F. Schultze-Lutter, et al., “The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe,” World Psychiatry, vol. 4, pp. 161–167, 2005.
[27]
S. Ruhrmann, F. Schultze-Lutter, R. K. R. Salokangas et al., “Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study,” Archives of General Psychiatry, vol. 67, no. 3, pp. 241–251, 2010.
[28]
A. R. Yung, H. P. Yuen, G. Berger et al., “Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?” Schizophrenia Bulletin, vol. 33, no. 3, pp. 673–681, 2007.
[29]
T. K. Larsen, I. Melle, B. Auestad et al., “Early detection of first-episode psychosis: the effect on 1-year outcome,” Schizophrenia Bulletin, vol. 32, no. 4, pp. 758–764, 2006.
[30]
J. Addington, I. Epstein, L. Liu, P. French, K. M. Boydell, and R. B. Zipursky, “A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis,” Schizophrenia Research, vol. 125, no. 1, pp. 54–61, 2011.
[31]
M. Marshall, A. Lockwood, S. Lewis, and M. Fiander, “Essential elements of an early intervention service for psychosis: the opinions of expert clinicians,” BMC Psychiatry, vol. 4, article no. 17, 2004.
[32]
N. C. Andreasen, W. T. Carpenter, J. M. Kane, R. A. Lasser, S. R. Marder, and D. R. Weinberger, “Remission in schizophrenia: proposed criteria and rationale for consensus,” American Journal of Psychiatry, vol. 162, no. 3, pp. 441–449, 2005.
[33]
S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987.
[34]
J. Van Os, M. Drukker, J. à. Campo, J. Meijer, M. Bak, and P. Delespaul, “Validation of remission criteria for schizophrenia,” American Journal of Psychiatry, vol. 163, no. 11, pp. 2000–2002, 2006.
[35]
S. Leucht and R. Lasser, “The concepts of remission and recovery in schizophrenia,” Pharmacopsychiatry, vol. 39, no. 5, pp. 161–170, 2006.
[36]
S. Leucht, J. M. Davis, R. R. Engel, J. M. Kane, and S. Wagenpfeil, “Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs,” Neuropsychopharmacology, vol. 32, no. 9, pp. 1903–1910, 2007.
[37]
S. Leucht, J. M. Davis, R. R. Engel, W. Kissling, and J. M. Kane, “Definitions of response and remission in schizophrenia: recommendations for their use and their presentation,” Acta Psychiatrica Scandinavica, vol. 119, no. 438, pp. 7–14, 2009.
[38]
J. E. Overall and D. R. Gorham, “The brief psychiatric rating scale,” Psychological Reports, vol. 10, no. 3, pp. 799–812, 1962.
[39]
R. Emsley, B. Chiliza, L. Asmal, and K. Lehloenya, “The concepts of remission and recovery in schizophrenia,” Current Opinion in Psychiatry, vol. 24, no. 2, pp. 114–121, 2011.
[40]
R. P. Liberman and A. Kopelowicz, “Recovery from schizophrenia: a concept in search of research,” Psychiatric Services, vol. 56, no. 6, pp. 735–742, 2005.
[41]
R. P. Liberman, A. Kopelowicz, J. Ventura, and D. Gutkind, “Operational criteria and factors related to recovery from schizophrenia,” International Review of Psychiatry, vol. 14, no. 4, pp. 256–272, 2002.
[42]
A. K. Torgalsb？en, “Full recovery from schizophrenia: the prognostic role of premorbid adjustment, symptoms at first admission, precipitating events and gender,” Psychiatry Research, vol. 88, no. 2, pp. 143–152, 1999.
[43]
A. K. Torgalsb？en and B. R. Rund, “Maintenance of recovery from schizophrenia at 20-year follow-up: what happened?” Psychiatry, vol. 73, no. 1, pp. 70–83, 2010.
[44]
M. Harrow, L. S. Grossman, T. H. Jobe, and E. S. Herbener, “Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study,” Schizophrenia Bulletin, vol. 31, no. 3, pp. 723–734, 2005.
[45]
B. Schrank and M. Slade, “Recovery in psychiatry,” Psychiatric Bulletin, vol. 31, no. 9, pp. 321–325, 2007.
[46]
D. Whitehorn, J. Brown, J. Richard, Q. Rui, and L. Kopala, “Multiple dimensions of recovery in early psychosis,” International Review of Psychiatry, vol. 14, no. 4, pp. 273–283, 2002.
[47]
C. M. Harding, G. W. Brooks, T. Ashikaga, et al., “The Vermont Longitudinal Study of persons with severe mental illness, II: long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia,” American Journal of Psychiatry, vol. 144, no. 6, pp. 727–735, 1987.
[48]
Asociación Psiquiátrica Americana, “Manual diagnóstico y estadístico de los trastornos mentales DSM-IV,” Evaluación de la Actividad Global (GAF), Masson S. A., Barcelona, Spain, 1995.
[49]
P. J. Weiden and A. Zygmunt, “Medication noncompliance in schizophrenia: part I. Assessment,” Journal of Practical Psychiatry and Behavioral Health, vol. 3, no. 2, pp. 106–110, 1997.
[50]
G. Harrison, K. Hopper, T. Craig et al., “Recovery from psychotic illness: a 15- and 25-year international follow-up study,” British Journal of Psychiatry, vol. 178, pp. 506–517, 2001.
[51]
L. Wunderink, S. Sytema, F. J. Nienhuis, and D. Wiersma, “Clinical recovery in first-episode psychosis,” Schizophrenia Bulletin, vol. 35, no. 2, pp. 362–369, 2009.
[52]
Asociación Psiquiátrica Americana, “Manual diagnóstico y estadístico de los trastornos mentales DSM-IV,” Masson S. A., Barcelona, Spain, 1995.
[53]
L. N. Robins, J. Wing, H. U. Wittchen et al., “The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures,” Archives of General Psychiatry, vol. 45, no. 12, pp. 1069–1077, 1988.
[54]
M. Valencia, M.-L. Rascon, and H. Ortega, “Psychosocial treatment in patients with schizophrenia,” in Schizophrenia: Current Views and Perspectives, H. Ortega and M. Valencia, Eds., pp. 399–454, Editorial Lasser, México City, Mexico, 2001.
[55]
C. J. Wallace, R. P. Liberman, S. J. MacKain, G. Blackwell, and T. A. Eckman, “Effectiveness and replicability of modules for teaching social and instrumental skills to the severely mentally ill,” American Journal of Psychiatry, vol. 149, no. 5, pp. 654–658, 1992.
[56]
R. P. Liberman and P. W. Corrigan, “Designing new psychosocial treatments for schizophrenia,” Psychiatry, vol. 56, no. 3, pp. 238–249, 1993.
[57]
A. Kopelowicz, R. Zarate, V. Gonzalez Smith, J. Mintz, and R. P. Liberman, “Disease management in Latinos with schizophrenia: a family-assisted, skills training approach,” Schizophrenia Bulletin, vol. 29, no. 2, pp. 211–227, 2003.
[58]
S. R. Kay, A. Fiszbein, M. Vital-Herne, and L. S. Fuentes, “The positive and negative syndrome scale—Spanish adaptation,” Journal of Nervous and Mental Disease, vol. 178, no. 8, pp. 510–517, 1990.
[59]
J. G. Csernansky and E. K. Schuchart, “Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics,” CNS Drugs, vol. 16, no. 7, pp. 473–484, 2002.
[60]
I. Lipkovich, W. Deberdt, J. G. Csernansky et al., “Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy,” Journal of Psychiatric Research, vol. 41, no. 3-4, pp. 305–310, 2007.
[61]
J. Cohen, Statistical Power Analysis for the Behavioral Sciences, Academia Press, New York, NY, USA, 1977.
[62]
A. E. Kazdin, “The meanings and measurement of clinical significance,” Journal of Consulting and Clinical Psychology, vol. 67, no. 3, pp. 332–339, 1999.
[63]
SPSS, “Statistical Package for Social Sciences,” Windows Version 11.5, SPSS, Chicago, Ill, USA, 2002.
[64]
C. Schmidt-Kraepelin, B. Janssen, and W. Gaebel, “Prevention of rehospitalization in schizophrenia: results of an integrated care project in Germany,” European Archives of Psychiatry and Clinical Neuroscience, vol. 259, no. 2, pp. S205–S212, 2009.
[65]
M. Sungur, H. Soygur, P. Guner, B. Ustun, I. Cetin, and I. A. N. Falloon, “Identifying an optimal treatment for schizophrenia: a 2-tear randomized controlled trial comparing integrated care to a high-quality routine treatment,” International Journal of Psychiatry in Clinical Practice, vol. 15, pp. 118–127, 2011.
[66]
L. Skalli and L. Nicole, “Specialised first-episode psychosis services: a systematic review of the literature,” Encephale, vol. 37, no. 1, pp. S66–S76, 2011.
[67]
V. Roder, D. R. Mueller, and S. J. Schmidt, “Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a research update,” Schizophrenia Bulletin, vol. 37, supplement 2, pp. S71–S79, 2011.
[68]
M. Valencia, E. Murow, and M. L. Rascón, “Comparación de tres modalidades de intervención en esquizofrenia: terapia psicosocial, musicoterapia y terapias múltiples,” Revista Latinoamericana de Psicologia, vol. 38, no. 3, pp. 535–549, 2006.
[69]
M. Valencia, M. L. Rascon, F. Juarez, and E. Murow, “A psychosocial skills training approach in Mexican out-patients with schizophrenia,” Psychological Medicine, vol. 37, no. 10, pp. 1393–1402, 2007.
[70]
M. Valencia, M. L. Rascon, F. Juarez, R. Escamilla, R. Saracco, and R. P. Liberman, “Application in Mexico of psychosocial rehabilitation with schizophrenia patients,” Psychiatry, vol. 73, no. 3, pp. 248–263, 2010.
[71]
M. Valencia, M. L. Rascón, and H. Quiroga, “Research contributions on psychosocial treatment and family therapy for patients with schizophrenia,” Salud Mental, vol. 26, no. 5, pp. 1–18, 2003.
[72]
K. T. Mueser, A. S. Bellack, J. H. Wade, S. L. Sayers, and C. K. Rosenthal, “An assessment of the educational needs of chronic psychiatric patients and their relatives,” British Journal of Psychiatry, vol. 160, pp. 674–680, 1992.
